Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04227470
Other study ID # 9161.2
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 31, 2020
Est. completion date December 24, 2021

Study information

Verified date January 2022
Source Harbour BioMed (Guangzhou) Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objectives:To investigate the safety and tolerability of HBM 9161 in patients with attack of NMOSD in China


Description:

This is an open-label, dose exploration study.The investigational drug is HBM9161 injection, and the indication is NMOSD. HBM9161(HL161BKN) is a human monoclonal antibody. HBM9161 targets the neonatal Fc receptor (FcRn) . By blocking the FcRn IgG-Fc binding site and accelerating the degradation of IgG, it can significantly reduce the total IgG level in blood (including pathological IgG).The serum aquaporin 4 antibody (AQP4-IgG) associated with NMOSD is a pathological IgG, so the combination of standard of care which is intravenous methylprednisolone (ivMP) with HBM9161 is expected to rapidly reduce AQP4-IgG levels. Two dose groups (340 mg and 680 mg) were planned, and each dose group plans to enroll approximately 6 subjects. All subjects are weekly administered the HBM9161 by subcutaneous injection for a period of 4 weeks, together with standard of care which is of intravenous methylprednisolone (ivMP) by subcutaneous for a period of 4 weeks. The study will investigate the safety, and tolerability, pharmacodynamics and efficacy of HBM 9161 in patients with attack of NMOSD in China.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date December 24, 2021
Est. primary completion date December 3, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. In visit 1, Male or female aged = 18 years. 2. Patient with NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis). 3. Core clinical manifestations characterized by new acute optic neuritis and/or transverse myelitis. A clinical event is defined as an episode of inflammation in the spinal cord and/or optic nerve leading to neurologic deficits which can be identified by physical examination and not attributable to another disease process. 4. The EDSS score should be = 2.5 and =7.5 at visit 1. 5. AQP4-IgG is positive at visit 1 or had AQP4-IgG positive medical records before visit 1. 6. Be able to recognize English letters. 7. Patients should be on stable treatment of the following medications before screening (if anyone had a stable treatment ): - Immunosuppressant or immunomodulatory drugs (for example, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, methotrexate and so on) must be stable for at least 8 weeks before screening and keep stable during study • Corticosteroids - At screening, the treatment dose must be stable for at least 1 month. • If patients accepted plasmapheresis or IVIg treatment, the last treatment dose/procedure must be finished at least 4 weeks ago before screening Exclusion Criteria: 1. No acute optic neuritis and/or transverse myelitis symptoms or signs. 2. Severe NMOSD which may require plasmapheresis or intravenous immunoglobulin (IVIG) treatment, in opinion of investigator, very soon. 3. Have received plasmapheresis or IVIG treatment, the last treatment dose/procedure is less than 4 weeks before visit 1. 4. Have known autoimmune diseases other than NMOSD that would interfere with efficacy assessment or participation in this study (such as uncontrolled thyroid disease or severe rheumatoid arthritis), or have any comorbid diseases which would interfere with the efficacy evaluation of HBM9161 on NMOSD. 5. Have received rituximab or other anti-CD20 drugs treatment within 6 months before visit 1. 6. Have been used any monoclonal antibodies or research drugs for immunomodulatory effects within 3 months before visit 1 or within 5 half-life periods of the drug. 7. Females who are pregnant or lactating. 8. Patients who can't tolerate or have contraindication to high dose intravenous methylprednisolone per Investigator's opinion. 9. Have active infection at screening, or recent serious infection (i.e., requiring intravenous antimicrobial therapy or hospitalization) within 8 weeks before screening; history of or existing infection of human immunodeficiency virus(HIV), hepatitis C virus (HCV), or Mycobacterium tuberculosis. Patients must have negative test results for HCV antibody, HIV 1 and HIV 2 antibodies, and a mycobacterium tuberculosis test (test method to be determined) at visit 1. 10. Patients have positive test result for HBsAg; or HBsAg negative meanwhile HBcAb positive and HBV-DNA level>2000IU/mL. 11. Serum total IgG <700mg/dL at visit 1. 12. Absolute neutrophil count <1500?/mm3 at visit 1 and/or visit 2 13. Patients with acute liver function impairment (e.g., hepatitis) or severe liver cirrhosis (Child-Pugh Score, Class C) 14. Any malignant tumor.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HBM9161 Injection
Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.

Locations

Country Name City State
China Nanfang Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Harbour BioMed (Guangzhou) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Maximum change from baseline to week 27 in total serum AQP4-IgG concentrations Maximum change from baseline in total serum AQP4-IgG concentrations 189 days
Other AQP4-IgG changes from baseline to week 27 Change of serum concentration of AQP4-IgG overtime after administration of HBM9161 from baseline to week 27 189 days
Other HBsAb level changes from baseline to week 27 Change in HBsAb level overtime after administration of HBM9161 from baseline to week 27 189 days
Primary Number of treatment related adverse events (AEs) Number of treatment related adverse events (AEs) 189 days
Secondary Immunoglobins changes from baseline to week 27 Change of concentration of immunoglobins in mg/ml overtime after administration of HBM9161 from baseline to week 27 189 days
Secondary Neurological Disability changes from baseline to week 27 Neurological Disability changes from baseline to week 27 as measured by Expanded Disability Scale Score (EDSS, Score 0-10, higher means a worse outcome) 189 days
Secondary Low Contrast Visual Acuity (LCVA) changes from baseline to week 27 Low Contrast Visual Acuity (LCVA) changes from baseline to week 27 as measured by Sloan Low Contrast Letter Scale (SLCLS Letter, Score 0-70, higher means a better outcome) 189 days
Secondary Patient reported improvement changes from baseline to week 27 Patient reported improvement changes from baseline to week 27 as measured by Patient Global Impression-Improvement (PGI-I, Score 1-7, higher means a worse outcome) 189 days
Secondary Percentage of patients who received rescue therapy Percentage of patients who received rescue therapy 189 days
Secondary Percentage of patients who have relapse Percentage of patients who have relapse 189 days
Secondary Walking ability changes from baseline to week 27 Walking ability changes from baseline to week 27 as measured by time used for 25-foot Walk (applicable for patients who are able to walk) 189 days
Secondary The seropositive rate of anti-HBM9161 antibody after treatment Evaluation of the seropositive rate of anti-HBM9161 antibody after treatment 189 days
See also
  Status Clinical Trial Phase
Recruiting NCT05154734 - Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Phase 1/Phase 2
Withdrawn NCT03829566 - Autologous Transplant To End NMO Spectrum Disorder Phase 2/Phase 3
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT05432713 - A Study of LP-168 in Healthy Volunteers Phase 1
Not yet recruiting NCT04822623 - Imaging Evaluation of Central Nervous Autoimmune Diseases
Not yet recruiting NCT06280755 - Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Recruiting NCT05414890 - Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Recruiting NCT05840055 - ACT With NMOSD Patients and Caregivers Pilot Study N/A
Recruiting NCT05004493 - Biorepository and Registry for Plasma Exchange Patients
Completed NCT05896605 - Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder Phase 4
Recruiting NCT04106830 - Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
Completed NCT03766347 - Pediatric NMOSD Observational Study
Recruiting NCT05154370 - China National Registry of Neuro-Inflammatory Diseases
Recruiting NCT06443333 - National, Multicentric Registry Study on Neuroimmunological Diseases in China
Recruiting NCT05145361 - Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) Early Phase 1
Not yet recruiting NCT05974293 - A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Phase 2
Completed NCT04355611 - Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
Recruiting NCT05792462 - Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders Phase 1/Phase 2